William Link, PhD Biography and Net Worth

Director of Tarsus Pharmaceuticals

Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. He has over two decades of operations experience in the healthcare industry and specializes in early-stage investing in medical devices. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital. He was previously Founder, Chairman and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of their successor company, Advanced Medical Optics, which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016. Before entering the healthcare industry, he was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the boards of RxSight, Inc. (NASDAQ: RXST), LENSAR, Inc. (NASDAQ: LNSR), and several private companies. He previously served on the board of Edwards Lifesciences (NYSE: EW), Glaukos (NYSE: GKOS) and Oyster Point Pharma, Inc. (NASDAQ: OYST). He received his BS, MS and PhD from Purdue University.

What is William J. Link, PhD's net worth?: The estimated net worth of William J. Link, PhD is at least $11.73 million as of September 8th, 2025. Dr. Link, PhD owns 143,332 shares of Tarsus Pharmaceuticals stock worth more than $11,728,858 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Link, PhD may own. Learn More about William J. Link, PhD's net worth.
How do I contact William J. Link, PhD?: The corporate mailing address for Dr. Link, PhD and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at [email protected]. Learn More on William J. Link, PhD's contact information.
Has William J. Link, PhD been buying or selling shares of Tarsus Pharmaceuticals?: William J. Link, PhD has not been actively trading shares of Tarsus Pharmaceuticals within the last three months. Most recently, William J. Phd Link sold 27,116 shares of the business's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $57.00, for a transaction totalling $1,545,612.00. Following the completion of the sale, the director now directly owns 143,332 shares of the company's stock, valued at $8,169,924. Learn More on William J. Link, PhD's trading history.
Who are Tarsus Pharmaceuticals' active insiders?: Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), Andrew Goldberg (Director), Leonard Greenstein (CFO), Elizabeth Lin (Director), William Link, PhD (Director), Aziz Mottiwala (Insider), Seshadri Neervannan (COO), Bryan Wahl (General Counsel), and Dianne Whitfield (Chief Human Resources Officer). Learn More on Tarsus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Tarsus Pharmaceuticals?: During the last year, insiders at the sold shares 10 times. They sold a total of 71,658 shares worth more than $3,759,005.28. The most recent insider tranaction occured on September, 24th when CEO Bobak R Azamian sold 6,000 shares worth more than $332,220.00. Insiders at Tarsus Pharmaceuticals own 9.0% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.
Information on this page was last updated on 9/24/2025.

William J. Link, PhD Insider Trading History at Tarsus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/8/2025	Sell	27,116	$57.00	$1,545,612.00	143,332

William J. Link, PhD Buying and Selling Activity at Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Today's Range

Now: $81.83

$80.14

$82.90

50 Day Range

MA: $71.50

$56.29

$82.11

2 Week Range

Now: $81.83

$38.51

$83.47

Volume

303,639 shs

Average Volume

389,914 shs

Market Capitalization

$3.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74